LALPATHLAB Buy Hold or Sell Recommendation

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>DL</div>
LALPATHLAB -- India Stock  

INR 1,782  132.70  6.93%

Assuming the 30-days trading horizon, and your above-average risk tolerance our recommendation regarding DR LAL PATHLABS is 'Sell'. Macroaxis provides DR LAL buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding DR LAL positions. The advice algorithm takes into account all of DR LAL PATHLABS available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from DR LAL buy-and-hold perspective. Additionally, see DR LAL Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool.

Search Advice

 
Refresh

Time Horizon

Risk Tolerance

Execute Advice
Sell DR LALBuy DR LAL
Sell

Volatility

Hype Condition

Current Valuation

Odds of Distress

Analyst Consensus

Not Available
For the selected time horizon DR LAL PATHLABS has a mean deviation of 1.63, semi deviation of 1.72, standard deviation of 2.32, variance of 5.39, downside variance of 5.05 and semi variance of 2.95
Macroaxis provides buy or sell advice on DR LAL PATHLABS to complement and cross-verify current analyst consensus on DR LAL. Our buy, hold, or sell suggestions engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. To make sure DR LAL PATHLABS is not overpriced, please confirm all DR LAL PATHLABS fundamentals, including its current valuation, price to sales, cash per share, as well as the relationship between the shares owned by institutions and ebitda .

DR LAL Trading Alerts and Improvement Suggestions

About 60.0% of the company outstanding shares are owned by corporate insiders

DR LAL current analysts advice

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. LALPATHLAB analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. LALPATHLAB analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Median Price1,012.50
Target Mean Price998.00
Recommendation Mean2.30
Target High Price1,320.00
Number Of Analyst Opinions14
Target Low Price720.00
The consensus estimates and target price estimation is comprised of individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.

DR LAL Returns Distribution Density

The chart of the probability distribution of DR LAL stock daily returns describes the distribution of returns around its average expected value. We use DR LAL PATHLABS' stock's Value At Risk and its Upside Potential as a relative measure of the distribution. The distribution of DR LAL returns is essential to provide solid investment advice for DR LAL stock.
Mean Return0.29Value At Risk-3.05
Potential Upside5.16Standard Deviation2.32
 Return Density 
      Distribution 
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of DR LAL historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

DR LAL Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to DR LAL or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that DR LAL stock's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a LALPATHLAB stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over DOW
=0.28
β
Beta against DOW=-0.04
σ
Overall volatility
=2.40
Ir
Information ratio =0.0256

DR LAL Volatility Alert

DR LAL PATHLABS currently demonstrates below-verage downside deviation of 2.25. It has Information Ratio of 0.03 and Jensen Alpha of 0.28. However, we do advice investors to further question DR LAL PATHLABS expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.
    
 Better Than Average     
    
 Worse Than Average Compare DR LAL to competition

DR LAL Fundamental Vs Peers

FundamentalsDR LALPeer Average
Return On Equity22.70 %(0.31) %
Return On Asset13.73 %(0.14) %
Profit Margin16.98 %(1.27) %
Operating Margin20.35 %(5.51) %
Current Valuation121.18 B16.62 B
Shares Outstanding83.34 M571.82 M
Shares Owned by Insiders60.36 %10.09 %
Shares Owned by Institutions31.42 %39.21 %
Price to Earning57.31 X28.72 X
Price to Book12.53 X9.51 X
Price to Sales9.83 X11.42 X
Revenue13.3 B9.43 B
Gross Profit7.89 B27.38 B
EBITDA3.44 B3.9 B
Net Income2.26 B570.98 M
Cash and Equivalents7.67 B2.7 B
Cash per Share93.00 X5.01 X
Current Ratio3.93 X2.16 X
Book Value Per Share125.21 X1.93 K
Cash Flow from Operations2.84 B971.22 M
Earnings Per Share27.37 X3.12 X
Price to Earnings To Growth2.03 X4.89 X
Number of Employees4.19 K18.84 K
Beta0.45-0.15
Market Capitalization130.73 B19.03 B
Total Asset7.42 B29.47 B
Working Capital4.07 B1.48 B
Current Asset5.11 B9.34 B
Current Liabilities1.05 B7.9 B
Z Score1.08.72
Last Dividend Paid15.5

About DR LAL Buy or Sell Advice

When is the right time to buy or sell DR LAL PATHLABS? Buying stocks such as DR LAL isn't very hard. However, what challenging for most investors is doing it at the right time to beat the stock market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily bases. Although DR LAL investors may find it confusing at the beginning, most of our advising modules are very easy to use and apply. Please read more on our stock advisor page.

Did You Try This Idea?

Run Insurance Providers Thematic Idea Now

Insurance Providers
Insurance Providers Theme
Companies providing all types of insurance and insurance services. Insurance Providers theme has 30 constituents.
View All  Next Launch Insurance Providers
Additionally, see DR LAL Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments please use Instant Ratings tool. Please also try Stock Screener module to find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page